New Delhi, May 14 -- Pharma major Zydus Lifesciences will be in focus today after it informed exchanges that its Board of Directors will consider a proposal for buyback of fully paid-up equity shares at its upcoming meeting scheduled for May 19, 2026, along with the company's financial results.

In a regulatory filing issued on May 13, the pharmaceutical major said the board would evaluate the buyback proposal in accordance with applicable provisions under the Companies Act, SEBI Buy-back Regulations and other relevant laws.

".the Board of the Company, at its aforesaid meeting, will also consider the proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the...